|
rs969139366
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.
|
28541695 |
2017 |
|
rs11672691
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found an association of the aggressive PCa-associated allele G of rs11672691 with elevated transcript levels of two biologically plausible candidate genes, PCAT19 and CEACAM21, implicated in PCa cell growth and tumor progression.
|
30033361 |
2018 |
|
rs1285136498
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs201216664
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs121917887
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs767808984
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs773862672
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs4987188
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |
|
rs17217772
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |
|
rs1284806277
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1284806277
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Stable S100P knockdown CRC cell lines were established to elucidate the relationship between S100P expression and tumor progression in vitro and in vivo.
|
26975699 |
2016 |
|
rs11568818
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The -181A→G (rs11568818) polymorphism in the MMP7 promoter modulates gene expression and possibly affects cancer progression.
|
25847246 |
2015 |
|
rs367597251
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Taken together, our results demonstrate that mutant C174Y possesses features that can positively contribute to cancer progression.
|
11004663 |
2000 |
|
rs55958994
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
|
31328168 |
2019 |
|
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
|
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
|
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras(G12D) activation and do not show a potent tumor suppressor response.
|
22532587 |
2012 |
|
rs1057519710
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of a 17-cm malignant GIST in the index patient revealed that it was hemi/homozygous for the germline D820Y mutation, indicating loss of the remaining wild-type KIT allele with tumor progression.
|
16327443 |
2005 |
|
rs77375493
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
|
23558526 |
2013 |
|
rs2016347
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
In multivariable analysis, patients with primary invasive breast cancer carrying IGF1R_rs2016347 G allele had a significantly increased risk of early tumor progression (hazard ratio (HR) 2.01; adjusted P=0.004) and death (HR 1.84; adjusted P=0.023) compared with patients carrying G/T or T/T, independent of established clinicopathological determinants.
|
23459444 |
2014 |
|
rs727503094
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs104894230
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs11549467
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |